Fiche publication
Date publication
novembre 2026
Journal
Neurology(R) neuroimmunology & neuroinflammation
Auteurs
Membres identifiés du Cancéropôle Est :
Pr DE SEZE Jérôme
Tous les auteurs :
Wingerchuk DM, Bennett JL, Berthele A, Clardy SL, Kim HJ, Nakahara J, de Sèze J, Kinoshita M, Sharma B, Uchida CL, Deeb Bou-Chahine R, Parks B, Allen K, Stankowski JN, Pittock SJ
Lien Pubmed
Résumé
Glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) are biomarkers of astrocytic and axonal injury, respectively, in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4-Ab+ NMOSD). We evaluated serum GFAP and NfL levels during treatment with complement component 5 inhibitors eculizumab or ravulizumab and examined associations between pretreatment biomarker levels, clinical characteristics, and on-trial relapse risk using samples from the PREVENT (eculizumab) and CHAMPION-NMOSD (ravulizumab) phase 3 trials.
Mots clés
Humans, Glial Fibrillary Acidic Protein, blood, Female, Aquaporin 4, immunology, Neurofilament Proteins, blood, Male, Biomarkers, blood, Neuromyelitis Optica, drug therapy, Adult, Middle Aged, Astrocytes, pathology, Axons, pathology, Antibodies, Monoclonal, Humanized, pharmacology, Retrospective Studies, Autoantibodies, blood
Référence
Neurol Neuroimmunol Neuroinflamm. 2026 11;13(6):e200661
